Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which has completed Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; OV882 as a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was incorporated in 2014 and is headquartered in New York, New York.
IPO Year: 2017
Exchange: NASDAQ
Website: ovidrx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/18/2024 | Outperform → Perform | Oppenheimer | |
4/30/2024 | $9.00 | Buy | B. Riley Securities |
4/29/2024 | $9.00 | Buy | H.C. Wainwright |
4/5/2024 | $8.00 | Outperform | Wedbush |
12/21/2023 | $11.00 | Buy | BTIG Research |
10/13/2023 | $8.00 | Outperform | Oppenheimer |
8/25/2021 | $4.50 → $4.00 | Neutral | Citigroup |
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
S-8 - Ovid Therapeutics Inc. (0001636651) (Filer)
10-Q - Ovid Therapeutics Inc. (0001636651) (Filer)
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
ARS - Ovid Therapeutics Inc. (0001636651) (Filer)
DEF 14A - Ovid Therapeutics Inc. (0001636651) (Filer)
DEFA14A - Ovid Therapeutics Inc. (0001636651) (Filer)
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander promoted to Chief Strategy OfficerOvid streamlined G&A infrastructure to improve operational efficiency and reduce costs NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today announced leadership appointments intended to enhance the execution of its corporate strategy and the scientific stewardship of its therapeutic
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors. "We are very pleased to have Kevin join our Board of Directors. His experience transforming state-of-the-art science and novel platform technologies into commercial medicines will provide valuable perspective for Ovid's neuroscience development programs," said Jeremy Levin, D.Phil, MB BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. "Kevin's expertise across small molecule an
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. "Ovid is building the intellectual and scientific platform to tackle the big questions in neuroscience so as to develop new medicines. To that end, Ovid is deepening the expertise and strengths of our Scientific Advisory Board by the addition of key leaders in specific areas. According
Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in additional milestone payments, plus tiered double-digit royalties, up to 20%, on sales if soticlestat is commercializedEnding Q1'21 cash and cash equivalents balance of $233.1 million and reduced cash burn supports prioritization of resources to advance robust early-stage neuroscience pipeline and explore full ecosystem of complementary external innovation Company is actively pursuing business development opportunities to advance its early-stage neuroscience pipeline and is planning to evaluate clinic
NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Professor Robert S. Langer, Sc.D., as Chairman of its Scientific Advisory Board. "We welcome Professor Robert Langer, who has joined Ovid as the new Chair of our Scientific Advisory Board," said Amit Rakhit, M.D., MBA, President, Ovid Therapeutics. "Bob will help guide Ovid's strategy to tackle opportunities and scientific questions underlying disorders in the brain. His perspective will be invaluable as we advance our pipeline of next-genera
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosingOV888/GV101 capsule was shown to be biologically active in participants and elicited dose-dependent pharmacodynamic effects within the planned therapeutic dose rangeA Phase 2 study for the treatment of cerebral cavernous malformations is expected to initiate in the second half of 2024 NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedi
Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key secondary efficacy endpoints all with p-values ≤ 0.008Takeda's Skyway study in Lennox-Gastaut syndrome missed its primary endpoint of reduction in major motor drop seizuresSoticlestat had a consistent and favorable safety and tolerability profile in both studiesTakeda will move forward to discuss the totality of the data with regulatory authoritiesWith the upfront milestone payment received from Takeda in 2021, Ovid built a differentiated pipeline with novel programs, including two clinical program
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data are anticipated in Takeda's H1 2024 fiscal yearA Phase 1, double-blind, multiple-ascending dose trial evaluating OV888 (GV101) is complete; topline safety data are expected in H1 2024Ovid expects to initiate a Phase 2 clinical program studying OV888 (GV101) in cerebral cavernous malformations in H2 2024Cash, cash equivalents and marketable securities were $90.3 million as of March 31, 2024; this capital is expected to support operations into H1 2026 NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20, 2024, at 3:00 p.m. ET. A live webcast of the fireside chat can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approxim
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET. A live webcast of the Needham presentation can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 90 days. About Ovid Th
Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September 2024OV888 (GV101) is progressing on-track in a Phase 1, double-blind, multiple-ascending dose trial; a higher dose cohort has been added and no serious adverse events have been observed Feedback from a pre-IND session with the FDA supports potential initiation of a Phase 2 study of OV888 (GV101) in the second half of 2024Phase 1 study with OV329 continues to progress; data expected in the second half of 2024Cash, cash equivalents and marketable securities of $105.8 million as of
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a panel titled "Orphan Epilepsies" at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts. A live webcast of the TD Cowen panel discussion can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the l
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET. A live webcast of the Oppenheimer presentation can be accessed through the Events & Presentations section of the Company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for a
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that five posters featuring data supporting its OV329 and OV350 programs for th
Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome remain on track; Takeda anticipates regulatory filings in its fiscal year 2024 Ovid recently hosted an R&D Day during which the Company announced indication and formulation expansions associated with the OV329 and KCC2 direct activator programs Ovid expects to achieve five clinical and regulatory milestones for its wholly owned pipeline in the next 15 months NEW YORK, Nov. 03
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 price target.
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily dosingOV888/GV101 capsule was shown to be biologically active in participants and elicited dose-dependent pharmacodynamic effects within the planned therapeutic dose rangeA Phase 2 study for the treatment of cerebral cavernous malformations is expected to initiate in the second half of 2024
BTIG analyst Thomas Shrader maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $11 to $5.
B. Riley Securities analyst Kalpit Patel maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $9 to $3.
Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target from $3.5 to $1.2.
In the latest quarter, 6 analysts provided ratings for Ovid Therapeutics (NASDAQ:OVID), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 1 0 0 3M Ago 0 1 0 0 0 Analysts have recently evaluated Ovid Therapeutics and provided 12-month price targets. The average target is $6.92, accompanied by a high estimate of $9.00 and a low estimate of $3.00. Experiencing a 5.59% decline,
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $9 to $3.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on Monday. The Dow traded up 0.57% to 38,807.47 while the NASDAQ rose 1.22% to 17,904.35. The S&P 500 also rose, gaining, 0.95% to 5,483.45. Check This Out: Top 4 Risk Off Stocks That May Rocket Higher In Q2 Leading and Lagging SectorsConsumer staples shares jumped by 1.5% on Monday. In trading on Monday, real estate shares fell by 0.6%. Top Headline The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50. Equities Trading UP Mustang Bio, Inc. (NASDAQ:M
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday's regular session. The company's market cap stands at $14.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 62.17% to $5.66. The company's market cap stands at $3.2 million. ENDRA Life Sciences (NASDAQ:NDRA) shares increased by 32.33% to $0.14. The market value of their outstanding shares is at $2.3 million. Trxade Health (NASDAQ:MEDS) stock increased by 31.87% to $8.7. The company's market cap stands at $12.2 million. 180 Life Sciences (NASDAQ:ATNF) stock increased by 24.11% to $1.92. The company's market cap stands at $1.8 million. Mirum Pharmaceuticals (NASDAQ:MIRM) shares
Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform
B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00
Wedbush initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00
BTIG Research initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $11.00
Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $8.00
Citigroup reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $4.00 from $4.50 previously
Cantor Fitzgerald downgraded Ovid Therapeutics from Buy to Neutral and set a new price target of $4.00
UBS Group reiterated coverage of Ovid Therapeutics with a rating of Neutral and set a new price target of $5.00 from $4.00 previously
RBC Capital Mkts downgraded Ovid Therapeutics from Outperform to Sector Perform and set a new price target of $5.00
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)